• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

导管原位癌向浸润性乳腺癌亚型特异性进展的分子特征

Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.

作者信息

Lesurf Robert, Aure Miriam Ragle, Mørk Hanne Håberg, Vitelli Valeria, Lundgren Steinar, Børresen-Dale Anne-Lise, Kristensen Vessela, Wärnberg Fredrik, Hallett Michael, Sørlie Therese

机构信息

Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada; McGill Centre for Bioinformatics, McGill University, Montreal, QC H3G 1Y6, Canada; Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada.

Institute for Cancer Research and Department of Cancer Genetics, Oslo University Hospital, The Norwegian Radium Hospital, 0424 Oslo, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, 0318 Oslo, Norway.

出版信息

Cell Rep. 2016 Jul 26;16(4):1166-1179. doi: 10.1016/j.celrep.2016.06.051. Epub 2016 Jul 7.

DOI:10.1016/j.celrep.2016.06.051
PMID:27396337
Abstract

Breast cancer consists of at least five main molecular "intrinsic" subtypes that are reflected in both pre-invasive and invasive disease. Although previous studies have suggested that many of the molecular features of invasive breast cancer are established early, it is unclear what mechanisms drive progression and whether the mechanisms of progression are dependent or independent of subtype. We have generated mRNA, miRNA, and DNA copy-number profiles from a total of 59 in situ lesions and 85 invasive tumors in order to comprehensively identify those genes, signaling pathways, processes, and cell types that are involved in breast cancer progression. Our work provides evidence that there are molecular features associated with disease progression that are unique to the intrinsic subtypes. We additionally establish subtype-specific signatures that are able to identify a small proportion of pre-invasive tumors with expression profiles that resemble invasive carcinoma, indicating a higher likelihood of future disease progression.

摘要

乳腺癌至少由五种主要的分子“内在”亚型组成,这些亚型在癌前病变和浸润性疾病中均有体现。尽管先前的研究表明浸润性乳腺癌的许多分子特征在早期就已确立,但尚不清楚驱动进展的机制是什么,以及进展机制是否依赖于亚型或与亚型无关。我们从总共59例原位病变和85例浸润性肿瘤中生成了mRNA、miRNA和DNA拷贝数图谱,以便全面识别参与乳腺癌进展的那些基因、信号通路、过程和细胞类型。我们的研究提供了证据,表明存在与疾病进展相关的分子特征,这些特征是内在亚型所特有的。我们还建立了亚型特异性特征,能够识别一小部分具有类似于浸润性癌表达谱的癌前肿瘤,这表明未来疾病进展的可能性更高。

相似文献

1
Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.导管原位癌向浸润性乳腺癌亚型特异性进展的分子特征
Cell Rep. 2016 Jul 26;16(4):1166-1179. doi: 10.1016/j.celrep.2016.06.051. Epub 2016 Jul 7.
2
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.有证据表明,在乳腺导管癌进展过程中,细胞的分子变化先于形态学改变出现。
Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.
3
Subtype-specific micro-RNA expression signatures in breast cancer progression.乳腺癌进展中的亚型特异性微小RNA表达特征
Int J Cancer. 2016 Sep 1;139(5):1117-28. doi: 10.1002/ijc.30142. Epub 2016 May 9.
4
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.通过深度测序 microRNA 定义的侵袭性和预后的乳腺癌特征。
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3024-9. doi: 10.1073/pnas.1200010109. Epub 2012 Feb 6.
5
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.基于ERBB2状态的乳腺导管原位癌中的差异基因表达
Cancer Control. 2017 Jan;24(1):102-110. doi: 10.1177/107327481702400117.
6
A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.高级别导管原位癌的分子图谱
Cancer Res. 2015 Sep 15;75(18):3980-90. doi: 10.1158/0008-5472.CAN-15-0506. Epub 2015 Aug 6.
7
The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.转录调节因子TBX3促进乳腺癌从非侵袭性向侵袭性进展。
BMC Cancer. 2016 Aug 23;16(1):671. doi: 10.1186/s12885-016-2697-z.
8
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.浸润性乳腺癌肿瘤和导管原位癌(DCIS)的综合分子谱揭示了不同的血管和白细胞介素信号。
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. doi: 10.1073/pnas.1108781108. Epub 2011 Sep 9.
9
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.HER2/neu过表达/扩增在乳腺导管原位癌进展为浸润性癌过程中的作用。
Mod Pathol. 2002 Dec;15(12):1318-25. doi: 10.1097/01.MP.0000038462.62634.B1.
10
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.特定年龄段的乳腺癌基因表达特征,以及年轻女性中跨物种保守的潜在癌症进展标志物。
PLoS One. 2013 May 21;8(5):e63204. doi: 10.1371/journal.pone.0063204. Print 2013.

引用本文的文献

1
Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.纯导管原位癌的突变图谱及其与疾病预后和放疗反应的关联。
Breast Cancer Res. 2025 Jul 8;27(1):127. doi: 10.1186/s13058-025-02080-z.
2
Quality of Life Among Patients With Ductal Carcinoma In Situ.导管原位癌患者的生活质量
JAMA Netw Open. 2025 Jul 1;8(7):e2518887. doi: 10.1001/jamanetworkopen.2025.18887.
3
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial.
肿瘤性pSMAD2作为早期乳腺癌的预后生物标志物:来自随机SweBCG91RT试验的见解
Breast Cancer Res Treat. 2025 Jun 9. doi: 10.1007/s10549-025-07744-0.
4
Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion.信号素-7A促进巨噬细胞介导的乳腺上皮原位癌和导管原位癌侵袭。
Res Sq. 2025 May 15:rs.3.rs-6448305. doi: 10.21203/rs.3.rs-6448305/v1.
5
Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer.基质硬度诱导的IKBKE和MAPK8信号传导驱动了从导管原位癌到浸润性乳腺癌的表型转变。
Cell Commun Signal. 2025 Jun 4;23(1):269. doi: 10.1186/s12964-025-02276-y.
6
B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.HER2阳性导管原位癌中的B细胞与能量代谢:来自空间组学分析对乳腺癌进展的见解
Breast Cancer Res. 2025 Mar 21;27(1):44. doi: 10.1186/s13058-025-01990-2.
7
An Overview of Invasive Ductal Carcinoma (IDC) in Women's Breast Cancer.女性乳腺癌中浸润性导管癌概述
Curr Mol Med. 2025;25(4):361-371. doi: 10.2174/0115665240349468241113065031.
8
Tumor microenvironmental determinants of high-risk DCIS progression.高危导管原位癌进展的肿瘤微环境决定因素。
Res Sq. 2024 May 9:rs.3.rs-4126092. doi: 10.21203/rs.3.rs-4126092/v1.
9
Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study.β受体阻滞剂在导管原位癌患者中的应用与浸润性乳腺癌复发风险:一项瑞典回顾性队列研究。
Breast Cancer Res Treat. 2024 Sep;207(2):293-299. doi: 10.1007/s10549-024-07358-y. Epub 2024 May 19.
10
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.SOX11 的表观遗传激活与导管原位癌向浸润性乳腺癌的复发和进展相关。
Br J Cancer. 2024 Jul;131(1):171-183. doi: 10.1038/s41416-024-02697-5. Epub 2024 May 17.